Titan Pharmaceuticals, Inc. (TTNP)
Oct 2, 2025 - TTNP was delisted (reason: merged into BTTC).
4.610
-0.180 (-3.76%)
Inactive · Last trade price
on Oct 1, 2025
Titan Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | - | - | 0.18 | 0.56 | 1.53 | 4.84 | Upgrade
|
| Revenue Growth (YoY) | - | - | -66.97% | -63.50% | -68.46% | 85.72% | Upgrade
|
| Cost of Revenue | - | - | 1.91 | 4.76 | 5.89 | 6.39 | Upgrade
|
| Gross Profit | - | - | -1.73 | -4.2 | -4.37 | -1.55 | Upgrade
|
| Selling, General & Admin | 2.61 | 4.56 | 5.55 | 6.03 | 4.99 | 5.8 | Upgrade
|
| Operating Expenses | 2.61 | 4.56 | 5.55 | 6.03 | 4.99 | 5.8 | Upgrade
|
| Operating Income | -2.61 | -4.56 | -7.28 | -10.24 | -9.35 | -7.35 | Upgrade
|
| Interest Expense | - | - | - | - | - | -0.77 | Upgrade
|
| Interest & Investment Income | - | 0 | 0.01 | 0.05 | 0 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.2 | -0.15 | -0.05 | -0.02 | -0.08 | 0.79 | Upgrade
|
| EBT Excluding Unusual Items | -2.81 | -4.71 | -7.32 | -10.21 | -9.44 | -7.33 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 1.76 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.66 | -0.08 | Upgrade
|
| Pretax Income | -2.81 | -4.71 | -5.57 | -10.21 | -8.78 | -7.41 | Upgrade
|
| Earnings From Continuing Operations | -2.81 | -4.71 | -5.57 | -10.21 | -8.78 | -7.41 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | -10.84 | Upgrade
|
| Net Income | -2.81 | -4.71 | -5.57 | -10.21 | -8.78 | -18.24 | Upgrade
|
| Net Income to Common | -2.81 | -4.71 | -5.57 | -10.21 | -8.78 | -18.24 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 16.31% | 19.55% | 11.91% | 38.13% | 157.89% | 392.56% | Upgrade
|
| EPS (Basic) | -2.95 | -5.23 | -7.41 | -15.19 | -18.04 | -96.70 | Upgrade
|
| EPS (Diluted) | -2.95 | -5.23 | -7.41 | -15.19 | -18.04 | -96.70 | Upgrade
|
| Free Cash Flow | -2.75 | -3.88 | -7.09 | -8.18 | -7.92 | -17.74 | Upgrade
|
| Free Cash Flow Per Share | -2.88 | -4.32 | -9.43 | -12.18 | -16.28 | -94.05 | Upgrade
|
| Gross Margin | - | - | - | - | -286.04% | -32.04% | Upgrade
|
| Operating Margin | - | - | -3954.89% | -1837.52% | -612.97% | -151.94% | Upgrade
|
| Profit Margin | - | - | -3026.63% | -1832.32% | -575.10% | -377.06% | Upgrade
|
| Free Cash Flow Margin | - | - | -3855.43% | -1469.12% | -519.13% | -366.74% | Upgrade
|
| EBITDA | -2.61 | -4.55 | -7.17 | -10.04 | -9.13 | -7.06 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -145.91% | Upgrade
|
| D&A For EBITDA | 0 | 0.01 | 0.11 | 0.2 | 0.22 | 0.29 | Upgrade
|
| EBIT | -2.61 | -4.56 | -7.28 | -10.24 | -9.35 | -7.35 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -151.94% | Upgrade
|
| Revenue as Reported | - | - | 0.18 | 0.56 | 1.53 | 4.84 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.